Skip To Main Content
Robby Weimer on Muck Rack

Robby Weimer

As seen in: Science Magazine, Cell Reports Medicine, JNeurosci
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Robby Weimer’s profile

Articles by Robby Weimer

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade

|
By Kabir Khan, Grant Li, Ping Xu, Alvin Gogineni, Robby Weimer, Annabelle Chow, Robert Piskol, Iacovos P. Michael, Weilan Ye, Robert Kerbel, Maresa Caunt Mitzner, William Cruz-Munoz, Patricia Himmels, Raj Jesudason
| Cell Reports Medicine Verified
Keywords tumor immunotherapy extracellular matrix cancer fibronectin integrin a5b1 combination atezolizumab Introduction A major benefit of immune checkpoint blockade in oncology includes the remarkable durable and major tumor remissions induced in some patients in a wide spectrum of different tumor types.1 Early trials involving Programmed Cell Death Protein-1 (PD-1) and Programmed death-ligand 1 (PD-L1) antibody inhibition monotherapy in patients with triple-negative breast cancer (TNBC)...
Open in Who Shared Issue with article?

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple Sclerosis

|
By Robby Weimer, Sean M. Silverman, Allison Soung, Stephen Vito
| JNeurosci Verified
Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple Sclerosis Ainhoa Etxeberria, Yun-An A. Shen, Stephen Vito, Sean M. Silverman, Jose Imperio, Guita Lalehzadeh, Allison L. Soung, Changchun Du, Luke Xie, Man Kin Choy, Yi-chun Hsiao, Hai Ngu, Chang Hoon Cho, Soumitra Ghosh, Gloriia Novikova, Mitchell G. Rezzonico, Rebecca Leahey, Martin Weber, Alvin Gogineni, Justin Elstrott, Monica Xiong, Jacob J. Greene, Kimberly L.
Open in Who Shared Issue with article?

Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of Alzheimer's Disease and Multiple Sclerosis

|
By Robby Weimer, Sean M. Silverman, Allison Soung, Steve Vito
| JNeurosci Verified
Research Articles, Neurobiology of Disease Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of Alzheimer's Disease and Multiple Sclerosis Ainhoa Etxeberria, Yun-An A. Shen, Steve Vito, Sean Silverman, Jose Imperio, Guita Lalehzadeh, Allison Soung, Changchun Du, Luke Xie, Man Kin Choy, Yi-chun Hsiao, Hai Ngu, Chang Hoon Cho, Soumitra Ghosh, Gloriia Novikova, Mitchell G. Rezzonico, Rebecca Leahey, Martin Weber, Alvin Gogineni, Justin Elstrott, Monica Xiong, Jacob J.
Open in Who Shared Issue with article?

Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease

|
By South San Francisco, Robby Weimer, William J. Meilandt, Sara Dominguez
| Science Magazine Verified
The genetics, pathology, and clinical manifestations of chronic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), are heterogeneous, which has made the development and testing of candidate therapeutics difficult. Here, Le Pichon et al. identify dual leucine zipper kinase (DLK) as a common regulator of neuronal degeneration in mouse models of ALS and Alzheimer’s disease and in human patient postmortem brain tissue.
Open in Who Shared Issue with article?
Show More